Abbott Pays Top Dollar to License Phase II Chronic Kidney Disease Therapy from Reata Pharmaceuticals
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 8 (Table of Contents)
Published: 18 Oct-2010
DOI: 10.3833/pdr.v2010.i8.1391 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Abbott Laboratories is paying US$450 M in upfront and near-term cash payments for the exclusive rights to develop and commercialise Reata Pharmaceuticals’ bardoxolone methyl outside of the US, Japan and certain other Asian countries...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS